Diabetes mellitus is a serious disease that arguably has reached global epidemic proportions. In their paper, Denise F. Messer, Claudia De Oliveira, Xiaoqiang Xue, Rick Turner and Erica Caveney of Quintiles scrutinisehow predictive analytics can facilitate more efficient study designs in development programmes for new antidiabetic drugs for type 2 diabetes mellitus (T2DM), with a brief recap of the essentials of the FDA and EMA guidelines and an account of how the drug development landscape has changed within the last decade or so.
https://international-pharma.com/wp-content/uploads/2014/10/Improving.pdf
Current Edition
Current Edition
Subsection - CDMO
Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.
Continue readingSubsection - Injectables
Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.
Continue readingSubsection - Neurodegenerative Diseases
Exploring emerging approaches to neurodegenerative disease research and treatment.
Continue readingSubsection - Nasal & Pulmonary
Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.
Continue reading
Improving Study Design in Diabetes Drug Development using Predictive Analytics
